ARTICLE | Finance
Kriya bulking up gene therapy R&D, infrastructure with $270M C round
Since last year’s $100M series B, Kriya has hired a CFO, presidents for oncology, ophthalmology and rare diseases
May 17, 2022 12:13 AM UTC
Kriya’s latest cash infusion brings the three-year-old preclinical gene therapy company’s total venture raise to $450.5 million, fueling a platform that spans four disease areas and includes in-licensed assets, internal R&D and in-house manufacturing.
Patient Square Capital led the $270 million series C round for Kriya Therapeutics Inc., announced Monday; it also led the company’s $100 million series B round last July. Other investors in the C round include Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT and Transhuman Capital. ...